Closed · RFA-CA-08-021 · CFDA 93.394;93.395 · Discretionary
SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44])
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- February 27, 2009
- Close date
- -
- Expected awards
The verdict
SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44]) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.394;93.395
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
SBIR Phase II Bridge Awards to Accelerate the… is closed (last close February 27, 2009). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed February 27, 2009
Est. Total Funding
$10,000,000
Instrument
Grant
Description
Purpose. This Funding Opportunity Announcement (FOA), launched as a pilot initiative at the National Institutes of Health (NIH) by the National Cancer Institute (NCI), solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional NIH funding to support the next stage of development for previously-funded NIH SBIR Phase II projects applicable to cancer therapies and cancer imaging technologies. The purpose of this FOA is to address the funding gap known as the Valley of Death between the end of the SBIR Phase II award and the commercialization stage. This FOA is also designed to promote partnerships between NIH s SBIR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital intensive steps that are required to commercialize new products/technologies emerging from NIH-funded SBIR Phase II projects. Applicants responding to this FOA must provide a specific commercialization plan that includes details on any independent third-party investor funding that has already been secured or is anticipated. It is expected that the level of this independent third-party funding will equal or exceed the NCI funds being requested throughout the Phase II Bridge Award project period. NCI support is thus intended to benefit cancer patients by accelerating the development of new cancer therapies (including anticancer agents and oncological therapeutic devices) and imaging devices/technologies toward commercialization. Only applications proposing projects in these areas will be considered responsive. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as needed but are not required.
Small-business / for-profit corridor · RFA-CA-08-021
SBIR Phase II Bridge Awards to Accelerate the… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).
- Code 23
- Small businesses
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
SBIR Phase II Bridge Awards to Accelerate the… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.394;93.395 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |